Rakuten Medical Secures $119 Million for Global Expansion of Precision Cell Targeting Therapies

In a significant advancement for cancer treatment, Rakuten Medical, Inc. has successfully raised $119 million in its latest funding round. As a trailblazer in the biotechnology sector, Rakuten Medical is committed to developing and commercializing precision therapies that harness the revolutionary Alluminox™ platform, which has demonstrated remarkable efficacy in pre-clinical studies by inducing rapid and selective cell killing as well as tumor necrosis. Currently headquartered in the United States, the company operates across five countries, including Japan, Taiwan, Switzerland, and India, reflecting its global ambition to combat cancer. This latest influx of capital will enhance Rakuten Medical's ability to expedite the clinical development of its novel therapies, which, while not yet approved outside of Japan, hold the promise of transforming cancer treatment for patients worldwide. The funding will primarily be allocated towards advancing ongoing clinical trials and expanding the company's research capabilities, ensuring that innovative solutions reach patients sooner. With a steadfast mission to conquer cancer and improve patient outcomes, Rakuten Medical continues to push the boundaries of biomedicine and aims to position itself at the forefront of oncology advancements. As Rakuten Medical embarks on this critical journey, the support from investors will enable it to accelerate its efforts in delivering life-saving therapies, bringing hope to countless individuals affected by cancer around the globe. To stay updated on Rakuten Medical's progress, visit www.rakuten-med.com.